NCT07690800CompletedPhase 4
Outcomes of Intravitreal Ranibizumab Injection for Diabetic Vitreous Hemorrhage
Outcomes of Intravitreal Ranibizumab Injection for Diabetic Vitreous Hemorrhage: A Prospective Interventional Cohort Study
Source: ClinicalTrials.gov · Last updated 8 Jul 2026
Brief summary (registry, in English)
This prospective interventional cohort study evaluates the outcomes of intravitreal ranibizumab injection in patients with diabetic vitreous hemorrhage secondary to proliferative diabetic retinopathy. The study aims to assess the effectiveness of ranibizumab in improving visual acuity, promoting vitreous hemorrhage clearance, reducing the need for pars plana vitrectomy, and evaluating treatment-related safety. Eligible adult patients with diabetic vitreous hemorrhage will receive intravitreal ranibizumab according to the study protocol and will be followed for 3 to 6 months with serial ophthalmic examinations. Outcome measures include changes in best-corrected visual acuity, vitreous hemorrhage severity, treatment-related complications, and the proportion of patients requiring vitrectomy. Panretinal photocoagulation may be performed when adequate retinal visualization is achieved.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 2 Jul 2026
- Start date
- Apr 2025
- Primary completion date
- Mar 2026
- Lead sponsor
- Benha University
- Diseases
- Diabetic eye disease
- NCT number
- NCT07690800
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 30
- From Apr 2025 to the primary completion date, Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Significant tractional retinal detachment or retinal traction requiring immediate surgery.
- Previous ocular surgery other than cataract surgery.
- Previous intravitreal pharmacologic treatment within the preceding 6 months.
Other illness
- Active ocular infection or significant ocular surface disease.
- Known hypersensitivity to ranibizumab or any component of the study medication.
Other
- Any type of glaucoma.
- No light perception vision.
- Refusal or inability to provide informed consent.
Who the study is looking for
- Adults aged 20 to 70 years.
- Type 1 or Type 2 diabetes mellitus.
- Diabetic vitreous hemorrhage secondary to proliferative diabetic retinopathy.
- Treatment-naïve diabetic vitreous hemorrhage or recurrent/residual vitreous hemorrhage following previous panretinal photocoagulation.
- Phakic or pseudophakic eyes.
- Able and willing to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Benha University Coordinator of this site? Confirm its status | Banhā | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.